Mobidiag, Bioportugal Collaborate
News Sep 27, 2016
Mobidiag Ltd has announced an agreement with Bioportugal Química Farmacêutica Lda for the distribution of the Amplidiag® product line. Under this agreement Bioportugal becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Portugal.
“For the past months, we have been extending significantly our European distribution network. With a strong background in diagnostics, Bioportugal seemed to be the clear choice to distribute our IVD tests in Portugal. We are then very pleased to expand even more Amplidiag accessibility with the support of Bioportugal” said Tuomas Tenkanen, CEO at Mobidiag.
“Bioportugal is one of the leader companies in the molecular diagnostic in Portugal and we have been supplying several branches world recognized for the last 15 years. Modidiag portfolio of products is perfect to complete our existing list. It was a gap in our portfolio and with Mobidiag range of products we expect to cover a more extensive list of clients, increase business and have a profitable relationship for both parts” said Joaquim Teixeira, CEO at Bioportugal.
The distribution agreement is effective immediately and covers all Amplidiag® products (Amplidiag® H. pylori+ClariR, Amplidiag® Stool Parasites, Amplidiag® CarbaR+VRE, Amplidiag® C. difficile+027, Amplidiag® Bacterial GE, Amplidiag® Easy and upcoming Amplidiag® Viral GE).
In recent years, numerous studies have shown that people who don't get enough sleep are at greater risk of stroke and heart attack. A study found that people who sleep fewer than 7 hours per night have lower blood levels of three physiological regulators, or microRNAs, which influence gene expression and play a key role in maintaining vascular health.